Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 105, Issue 6, Pages 713-722
Publisher
Wiley
Online
2014-04-09
DOI
10.1111/cas.12418
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate
- (2013) Kennosuke Karube et al. CANCER LETTERS
- Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
- (2013) K. F. Hui et al. MOLECULAR CANCER THERAPEUTICS
- Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell Lymphoma
- (2013) Takayuki Murata et al. PLoS One
- Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma
- (2012) K.F. Hui et al. INTERNATIONAL JOURNAL OF CANCER
- A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice
- (2011) K. Sato et al. BLOOD
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells
- (2011) Seiko Iwata et al. CANCER SCIENCE
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- (2011) Anastasios Stathis et al. CLINICAL CANCER RESEARCH
- Novel Mouse Xenograft Models Reveal a Critical Role of CD4+ T Cells in the Proliferation of EBV-Infected T and NK Cells
- (2011) Ken-Ichi Imadome et al. PLoS Pathogens
- Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection
- (2010) Seiko Iwata et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
- (2009) R. Suzuki et al. ANNALS OF ONCOLOGY
- How I treat EBV lymphoproliferation
- (2009) H. E. Heslop BLOOD
- Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
- (2009) D. Mahalingam et al. CLINICAL CANCER RESEARCH
- Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection
- (2009) S. Iwata et al. JOURNAL OF GENERAL VIROLOGY
- Epstein–Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis
- (2008) Y Isobe et al. BRITISH JOURNAL OF CANCER
- A New Humanized Mouse Model of Epstein‐Barr Virus Infection That Reproduces Persistent Infection, Lymphoproliferative Disorder, and Cell‐Mediated and Humoral Immune Responses
- (2008) Misako Yajima et al. JOURNAL OF INFECTIOUS DISEASES
- One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection
- (2007) Naomi Kubota et al. JOURNAL OF VIROLOGICAL METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started